Company: NCEL
Filing Date: 2025-01-28
Form Type: 425
Source: 0001213900-25-007315
Chunk: 3

Company: NewcelX Ltd.
Filing Date: 2025-01-28
Form: 425
Chunk 3
---
 Scientific Officer of NLSP. "Our stepwise development plan prioritizes
early-stage investment to generate critical data that will pave the way for larger-scale studies and potential commercialization opportunities."

Existing Patent Portfolio

NLS Pharmaceutics has secured several patents supporting the development
of Mazindol ER:

| ● | United States Patent No. 11,207,271: Covers oral formulations containing                                                  
 immediate-release and sustained-release layers of mazindol and their use in treating attention deficit disorders (“ADHD”) 
 as well as sleep disorders.                                                                                               |

| ● | United States Patent No. 11,596,622: Granted for the use of Mazindol                                    
 ER in the treatment of heroin dependence, providing a new therapeutic strategy for opioid use disorder. |

These patents strengthen the Company's intellectual property position
and support the ongoing development of Mazindol ER for various indications.

<div align='center'>2</div>

Future Outlook

NLS aims to utilize initial findings to expanded research and potential
commercialization of Mazindol ER in the treatment of fentanyl dependence. Other pipeline candidates include:

| ● | NLS-4 (Lauflumide): A wake-promoting agent with applications in military 
 and emergency response.                                                  |

| ● | NLS-11 (Benedin): A circadian rhythm modulator with potential applications 
 for space missions and the ultra-rare Kleine-Levin Syndrome (KLS).         |

| ● | NLS-3 (Levophacetoperane SR): A novel treatment for ADHD and Autism 
 Spectrum Disorders, with potential pro-drug development.            |

About NLS Pharmaceutics Ltd.

NLS is a global development-stage biopharmaceutical company, working
with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative
therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland
and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates.
NLS has recently filed a Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission (the “SEC”),
outlining the details of the proposed merger between NLS and Kadimastem (the “Merger”). Kadimastem is a leading clinical stage
cell therapy company, developing "off-the-shelf", proprietary cell products including human pancreatic islet-like cells capable